← Back to Patent Explorer
US4160018A Expired / Lapsed US ⏱️ 0.0 years remaining

Stabilized cancer associated polypeptide antigen and preparation thereof

Assignee: Individual
•
Filing: 1976-03-05
•
Granted: 1979-07-03
•
Expires: 1996-03-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A process for the isolation of cancer associated polypeptide antigen mainly by several steps of gel filtration and pH-gradient elution; a cancer associated polypeptide antigen based on a single peptide chain and denaturating irreversibly at pHs exceeding about 4.5; a composition comprising such antigen and a stabilizing amount of albumen in admixture therewith and a method of making such composition; a diagnostic composition comprising a particulate material labelled with albumen-stabilized antigen; process for preparing antibodies monospecific with regard to the cancer associated polypeptide antigen comprising preparing an oil emulsion, wherein an acid aqueous solution of the polypeptide is enclosed phase protected by a surrounding oil phase; a cancer diagnosis method based on determining the presence of cancer associated polypeptide antigen in a living animal body under examination; and composition useful as an immunizing agent containing as an active ingredient the cancer associated polypeptide antigen.

Inventors

  • 👤 Knut B. Bjorklund

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-25 22:11
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/5758; A; A61; A61K; A61K39/00; A61K39/0005; A61K39/0011; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/813; Y10S530/00; Y10S530/806; Y10S530/81; Y10S530/811; Y10S530/812; Y10S530/815; Y10S530/827; Y10S530/828; Y10S530/829; Y10S530/83; Y10S530/85; Y10S530/851

Claims Analysis

Total Claims: 7
Claim 1
Independent Claim 199 words
A method of making an antigen albumen complex comprising the steps of: mixing, in acid solution, at a pH not exceeding about 5, the antigen, said antigen being: a cancer associated polypeptide antigen, obtained from a source selected from the group consisting of human tumor tissue, a culture of cancerous cells grown in vitro, and human placental tissue, having a molecular weight of 23,200 ± 2,500 (S.D.) and showing a spectrophotometric peak absorption at a wave length within the range from about 229 nm to about 233 nm, said polypeptide being based on a single peptide chain as shown by treatment with performic acid, said single peptide chain comprising the following amino acids: Alanine, Arginine, Aspartic acid, Cysteine, Glutamic acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Serine, Threonine, Tyrosine, and Valine, said polypeptide antigen comprising also a fluoroescent group which emits fluorescent light at about 350 nm when activated at a wavelength of about 288 nm, and, if not protected by complexing with albumen, denaturating irreversibly at pH's exceeding about 5, and albumen, and raising the pH of the solution to about neutral to cause interaction between the components and production of a relatively stable antigen albumen complex.
Claim 2
Independent Claim 199 words
A method of making an antigen albumen complex comprising the steps of: mixing, in acid solution, at a pH not exceeding about 5, the antigen, said antigen being: a cancer associated polypeptide antigen, obtained from a source selected from the group consisting of human tumor tissue, a culture of cancerous cells grown in vitro, and human placental tissue, having a molecular weight of 23,200 ± 2,500 (S.D.) and showing a spectrophotometric peak absorption at a wave length within the range from about 229 nm to about 233 nm, said polypeptide being based on a single peptide chain as shown by treatment with performic acid, said single peptide chain comprising the following amino acids: Alanine, Arginine, Aspartic acid, Cysteine, Glutamic acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Serine, Threonine, Tyrosine, and Valine, said polypeptide antigen comprising also a fluoroescent group which emits fluorescent light at about 350 nm when activated at a wavelength of about 288 nm, and, if not protected by complexing with albumen, denaturating irreversibly at pH's exceeding about 5, and albumen, and raising the pH of the solution to about neutral to cause interaction between the components and production of a relatively stable antigen albumen complex.
Claim 3
Dependent Claim 14 words
A method according to claim 1, including the further step of lyophilizing the complex.
Claim 4
Dependent Claim 169 words
A complex, useful as a stabilized antigen for diagnostic purposes, comprising: a cancer associated polypeptide antigen, obtained from a source selected from the group consisting of human tumor tissue, a culture of cancerous cells grown in vitro, and human placental tissue, havng a molecular weight of 23,200 ± 2,500 (S.D.) and showing a spectrophotometric peak absorption at a wave length within the range from about 229 nm to about 233 nm, said polypeptide being based on a single peptide chain as shown by treatment with performic acid, said single peptide chain comprising the following amino acids: Alanine, Arginine, Aspartic acid, Cysteine, Glutamic acid, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Serine, Threonine, Tyrosine, and Valine, said polypeptide antigen comprising also a fluoroescent group which emits fluorescent light at about 350 nm when activated at a wavelength of about 288 nm, and if, not protected by complexing with albumen, denaturating irreversibly at pH's exceeding about 5, and a stabilizing amount of albumen complexed therewith by the method of claim 1.
Claim 5
Dependent Claim 22 words
The complex of claim 3, wherein the ratio of albumen to the antigen, is equal to about or exceeding 200:1 by weight.
Claim 6
Dependent Claim 15 words
A diagnostic composition comprising a particulate material labelled with the albumen-stabilized antigen of claim 3.
Claim 7
Dependent Claim 25 words
The diagnostic composition of claim 5, wherein the particulate material is selected from the group consisting of tanned red blood cells, latex bentonite and collodion.

References Cited (Backward Citations)

US3010875A Cited
US3551555A Cited
US3823126A Cited
US3968827A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1982-07-02 1983-01-01 1983-07-03 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1986-07-02 1987-01-01 1987-07-03 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1990-07-02 1991-01-01 1991-07-03 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag